A Randomized, Single-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 Compared to Placebo in T2DM Patients Treated With Metformin and Sulfonylurea.
Phase of Trial: Phase I
Latest Information Update: 25 Feb 2010
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 25 Feb 2010 Actual patient number (75) added as reported by ClinicalTrials.gov.
- 25 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2009 New trial record